AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03088059
Drug: IPH2201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Trial: NCT01057498
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNS60, 4ml nebulized twice daily for 15 minutes.
Trial: NCT01057498
Drug: RNS60 - single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNS60, single 4 ml dose nebulized for 15 minutes
Trial: NCT00683176
Drug: Choline Fenofibrate
RxNorm normalized name: Choline Fenofibrate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 135 mg
Trial: NCT00683176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01757015
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 (50µg, o.d. via SDDPI) in the morning,
Trial: NCT01757015
Drug: Placebo to NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to NVA237
Trial: NCT03571503
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Trial: NCT04150835
Drug: Xingnaojing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
Trial: NCT04150835
Drug: Xingnaojing placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
Trial: NCT04294069
Drug: Azithromycin 500 mg
RxNorm normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg azithromycin PO for seven days starting on admission
Trial: NCT04294069
Drug: Azithromycin Oral Product
RxNorm normalized name: azithromycin Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg azithromycin PO once at admission
Trial: NCT00568802
Drug: Placebo to match hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03717194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
Trial: NCT02777723
Drug: Xenobella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic 0.3% Sodium Hyaluronate
Trial: NCT04111965
Drug: Nanodrop®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: minimum to meet 1 drop 4 times a day, both eyes
Trial: NCT00548327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
Trial: NCT02027935
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00052039
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This study was terminated prior to enrollment.
Trial: NCT00002557
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03571594
Drug: ONO-5788 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT00002557
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002557
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002557
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02019355
Drug: 5-fluorouracil 5% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05104931
Drug: Nanoformed Piroxicam IR Tablet
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally delivered Nanoformed Piroxicam
Trial: NCT05104931
Drug: Felden (piroxicam) Tablets
RxNorm normalized name: piroxicam Oral Capsule [Feldene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally delivered Felden (reference) tablets
Trial: NCT05104931
Drug: Brexidol (piroxicam) Tablets
RxNorm normalized name: piroxicam Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally delivered Brexidol (reference) tablets
Trial: NCT00006480
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00375752
Drug: Zolendronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
Trial: NCT03369782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex
Trial: NCT01104649
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
Trial: NCT04326374
Drug: daily hGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily subcutaneous injection
Trial: NCT02169882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs.
Trial: NCT00690820
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00565474
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graft vasculopathy
Trial: NCT00662909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01269294
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of 75 mg once daily for 7 days in Treatment A
Trial: NCT01269294
Drug: Placebo for TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 placebo capsules once daily for 7 days in Treatment C
Trial: NCT01269294
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
Trial: NCT01269294
Drug: Placebo for TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules once daily for 7 days in Treatment A
Trial: NCT01269294
Drug: Placebo for TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 placebo capsules once daily for 7 days in Treatment D
Trial: NCT01140906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, daily, orally
Trial: NCT02112734
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo daily
Trial: NCT02397525
Drug: LIPO-202
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00947544
Drug: HPN-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
Trial: NCT00947544
Drug: NaPBA
RxNorm normalized name: Caffeine 200 MG Oral Powder for Suspension [SNAPBACK STIMULANT POWDERS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
Trial: NCT00299039
Drug: acetaminophen plus codeine
RxNorm normalized name: acetaminophen / codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules four times daily until pain free or for a maximum of seven days
Trial: NCT00299039
Drug: acetaminophen plus ibuprofen
RxNorm normalized name: acetaminophen / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules four times daily until pain free or for a maximum of seven days
Trial: NCT00026130
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
Trial: NCT01917019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets
Trial: NCT03257267
Drug: Investigator Choice (IC) Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC chemotherapy options include:~1. Antifolate: Pemetrexed~2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan~3. Nucleoside analogue: Gemcitabine~4. Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above.
Trial: NCT01563939
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg.
Trial: NCT00744341
Drug: SLV320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25mg i.v. bid
Trial: NCT00744341
Drug: SLV320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75mg i.v. bid
Trial: NCT00744341
Drug: SLV320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5mg i.v. bid
Trial: NCT00744341
Drug: SLV320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15.0mg i.v. bid
Trial: NCT00744341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01874860
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline capsule, 100 mg, taken twice daily
Trial: NCT01874860
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recommended for daily use if rash returns (Topical cream)
Trial: NCT02107274
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
Trial: NCT02107274
Drug: Placebo for Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
Trial: NCT03531905
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, matched for the FDC product for blinding purposes
Trial: NCT00756470
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
Trial: NCT03531905
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo over-encapsulated for blinding purposes
Trial: NCT01400100
Drug: sterile NaCl (sodium chloride) 0,9% solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
Trial: NCT00132626
Drug: [123I]ß-CIT and SPECT imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01060501
Drug: Folinic Acid, interferon-alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
Trial: NCT00038792
Drug: Recombinant Human Keratinocyte Growth Factor
RxNorm normalized name: Recombinant human keratinocyte growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02215460
Drug: FMS placebo rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Trial: NCT02215460
Drug: FMS azithromycin tablets
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Trial: NCT02215460
Drug: FMS placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Trial: NCT02215460
Drug: QS azithromycin tablets
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Trial: NCT02215460
Drug: QS placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Trial: NCT01251614
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
Trial: NCT01251614
Drug: Placebo to Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally once a week
Trial: NCT02892409
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin tablets
Trial: NCT02215460
Drug: QS placebo rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Trial: NCT00302419
Drug: intracoronary infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: streptokinase, 250,000 units
Trial: NCT02609490
Drug: Azilsartan placebo tablets
RxNorm normalized name: azilsartan Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT00058981
Drug: DiaPep277
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00189033
Drug: psyllium fibre (dietary supplement)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01548157
Drug: HCP1007 / omarco and crestor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCP1007 / Rosuvastatin plus Omega-3
Trial: NCT00666770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo 30 minutes prior to bedtime
Trial: NCT00751127
Drug: PhXA41
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in the affected eye once daily for six months.
Trial: NCT03098979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally once daily for 20 weeks
Trial: NCT02426684
Drug: IdeS® (Imlifidase)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.24mg/kg IdeS
Trial: NCT00259831
Drug: CVT-E002 (Cold-FX); a natural health product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01715298
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
Trial: NCT01715298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
Trial: NCT00883727
Drug: Plasmalyte A
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT01126424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03909217
Drug: Insomnia medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
Trial: NCT00426270
Drug: Octagam 10%
RxNorm normalized name: Octagam 10% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octagam 10% was supplied as a ready-to-use solution in glass bottles.
Trial: NCT03421431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets daily for 12 weeks
Trial: NCT04923152
Drug: moderate statin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg rosuvastatin per day
Trial: NCT04923152
Drug: high dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg rosuvastatin per day
Trial: NCT01030146
Drug: NeilMed® Sinus Rinse™ System with Isotonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
Trial: NCT01669239
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of:~* Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~* Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~* Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks
Trial: NCT00079937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
Trial: NCT02057770
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00527059
Drug: spironolactone, beta-blockers,ecc
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04111315
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibufen-L® tablets 500 mg 2-2-2
Trial: NCT00031447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical to oral acyclovir suspension in appearance and taste.
Trial: NCT00554164
Drug: (R-)CHOP protocol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
Trial: NCT00554164
Drug: (R-)CHOP protocol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
Trial: NCT00554164
Drug: (R-)CHOP protocol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
Trial: NCT04559308
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line neoadjuvant chemotherapy protocol